About Us
Bio-PrecisionAI Health was founded on November 27, 2023 and incorporated in April 2024. We build AI platforms for drug discovery by integrating predictive modeling, computational design, biomarker discovery, and scientific strategy across small molecules, biologics, and oligonucleotides.
-
Small molecule discovery platforms
Our AI workflowlows rank targets, refine candidate hypotheses, and improve early-stage molecular design decisions.
-
Biologics and oligonucleotide platforms
Our modality-aware computational workflows evaluate therapeutic stronger scientific direction.
-
Biomarker and translational intelligence
Our platforms analyze complex biological datasets to identify clinically meaningful signals and inform therapeutic development.
Leadership Team Members
Core Scientific Pillars
Discovery-Native Workflows
Strategy to Execution
AI Platforms for Drug Discovery
Bio-PrecisionAI Health develops integrated platform systems for target discovery and therapeutic candidate selection across modalities.
AI Drug Discovery Platforms
We build modular platforms spanning target prioritization, candidate design, and multimodal therapeutic discovery.
Integrated Modeling and Data
Our platform stack combines data integration, predictive modeling, and workflow automation to turn biological evidence into decisions.
Consulting
Consulting applies across every platform and modality, bringing scientific and computational expertise to target discovery, candidate design, bioinformatics, biomarkers, and translational strategy.
Consulting
Discuss how consulting can apply across one or more of our drug discovery platforms and therapeutic modalities.
Focus Areas
Our platform work spans the scientific and strategic areas required to turn AI insight into therapeutic design decisions.
Small Molecules
We apply AI-guided workflows to improve target prioritization, molecular design, and early candidate selection.
Our platforms evaluate target biology, chemical structure, and candidate behavior to sharpen hit identification and optimization priorities.
Biologics
Biologic discovery demands careful integration of modality knowledge, target biology, and design strategy.
Our biologics platform combines computational analysis across target biology, molecular design, and candidate prioritization to identify and refine therapeutic opportunities.
Oligonucleotides
Oligonucleotide discovery requires strong target logic, data interpretation, and modality-aware development planning.
Our oligonucleotide platform work combines target logic, sequence context, and data interpretation to guide modality-specific discovery decisions.
Biomarker Discovery
Biomarkers sharpen precision medicine programs by connecting biological signals to patient relevance.
We interpret complex genomic and multi-omics datasets to identify biomarker opportunities that support patient stratification, response prediction, and translational planning.
Scientific Strategy
Strong discovery programs need more than models. They need clear scientific choices and executable direction.
Scientific strategy directs our platform roadmap across modality selection, computational workflows, biomarker use, and validation priorities.
Our Team
The Bio-PrecisionAI Health team brings together scientific leadership, computational expertise, and company-building experience.
Board of Directors
Joseph Luper Tsenum, MS, MSc
Co-Founder, Chief Technology Officer and Chairman of the Board- PhD Candidate, Biomedical Engineering (Modeling and Biomedical Data Science), University of Florida
- MS, Professional Bioinformatics, Georgia Institute of Technology
- MSc, Applied Bioinformatics, Moscow Institute of Physics and Technology (MIPT)
- BSc, Biochemistry, UAM
Victoria Harper-Alexander, MS
Co-Founder, Chief Scientific Officer, Board Member- PhD Candidate, Biological and Biomedical Sciences, University of Central Florida
- MS, Biological and Biomedical Sciences, University of Central Florida
- BS, Neurobiology and Behavior, University of Florida
Company Leadership
Laras Salsabila, MDP
Chief Operating Officer- Master of Development Practice, Sustainable Development Practice, University of Florida
- BS, Communication and Community Development Sciences, IPB University
Dylan Tan
Director of Engineering: AI & Machine Learning- PhD Student, Biomedical/Medical Engineering (Modeling and Biomedical Data Science)
- BS, Biomedical Engineering, University of Florida
Ellie Okwei, PhD, MS
Head, Computational Drug Discovery- PhD, Chemistry; Biophysics; Computational Structural Biochemistry, Vanderbilt University
- MS, Chemistry, University of North Carolina at Charlotte
- BS, Chemistry/Biochemistry, University of Virginia
Advisory Board
Artem Kasianov, PhD, MS
Senior Data Scientist/Bioinformatician at Quantori- Expertise: Applied Mathematics, Bioinformatics, Computational Biology
Rufus Sha'Ato, PhD, MS
Professor of Analytical Chemistry at JOSTUM- Expertise: Chemistry, Analytical Chemistry
Frequently Asked Questions
Common questions about Bio-PrecisionAI Health's platforms and consulting work.
What does Bio-PrecisionAI Health build?
We build AI platforms for drug discovery across small molecules, biologics, and oligonucleotides, with biomarker intelligence and translational strategy built into the platform stack.
How does consulting fit across the platform work?
Consulting is the dedicated advisory layer across every modality. It supports target discovery, candidate design, bioinformatics, biomarker strategy, and translational planning for the platforms we build.
Where does scientific strategy fit into the platform?
Scientific strategy informs platform priorities and validation. Consulting applies across the company's modalities and platform areas when focused expertise is needed.
How do biomarker and precision medicine capabilities fit into the platform?
Biomarker discovery and translational analysis are integrated into our drug discovery platforms, identifying clinically relevant signals for patient stratification and therapeutic decisions.
How is a consulting discussion structured?
Use the consulting form to initiate a discussion spanning drug discovery platforms, biomarker strategy, or therapeutic modalities. For all other messages, use the general contact form.
How is consulting scoped across the platform?
Consulting is directed by the scientific question, available data, platform area, and decision points relevant to the cross-modality work.
Company Milestones
Selected scientific, product, and company milestones will be published here as they mature.
Gallery
A visual snapshot of our research, collaboration, innovation events, founder pitch moments, and industry conference presence.
Contact
Contact Bio-PrecisionAI Health about our AI platforms for drug discovery or cross-platform consulting.
Company
Bio-PrecisionAI Health